These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 31745354)

  • 21. Evaluating Temperature Sensitivity of Vesicular Stomatitis Virus-Based Vaccines.
    Stein DR; Sroga P; Warner BM; Deschambault Y; Poliquin G; Safronetz D
    Emerg Infect Dis; 2019 Aug; 25(8):1563-1566. PubMed ID: 31141474
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ebola outbreak continues despite powerful vaccine.
    Cohen J
    Science; 2019 Apr; 364(6437):223. PubMed ID: 31000645
    [No Abstract]   [Full Text] [Related]  

  • 23. Ebola epidemic in war-torn Democratic Republic of Congo, 2018: Acceptability and patient satisfaction of the recombinant Vesicular Stomatitis Virus - Zaire Ebolavirus Vaccine.
    Kasereka MC; Sawatzky J; Hawkes MT
    Vaccine; 2019 Apr; 37(16):2174-2178. PubMed ID: 30878249
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial.
    Martin JE; Sullivan NJ; Enama ME; Gordon IJ; Roederer M; Koup RA; Bailer RT; Chakrabarti BK; Bailey MA; Gomez PL; Andrews CA; Moodie Z; Gu L; Stein JA; Nabel GJ; Graham BS
    Clin Vaccine Immunol; 2006 Nov; 13(11):1267-77. PubMed ID: 16988008
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus.
    Wang D; Raja NU; Trubey CM; Juompan LY; Luo M; Woraratanadharm J; Deitz SB; Yu H; Swain BM; Moore KM; Pratt WD; Hart MK; Dong JY
    J Virol; 2006 Mar; 80(6):2738-46. PubMed ID: 16501083
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ebola and COVID-19 in DR Congo and Guinea.
    Adepoju P
    Lancet Infect Dis; 2021 Apr; 21(4):461. PubMed ID: 33773127
    [No Abstract]   [Full Text] [Related]  

  • 27. Long-term vaccine strategies for Ebola.
    Lauer KB; Faqih L; Blanchard TJ
    Lancet Infect Dis; 2015 May; 15(5):506-7. PubMed ID: 25932578
    [No Abstract]   [Full Text] [Related]  

  • 28. Congo rapidly curtails Ebola.
    Cohen J
    Science; 2018 Jul; 361(6399):211-212. PubMed ID: 30026204
    [No Abstract]   [Full Text] [Related]  

  • 29. Recent advances in the development of vaccines for Ebola virus disease.
    Ohimain EI
    Virus Res; 2016 Jan; 211():174-85. PubMed ID: 26596227
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluating Ebola vaccine trials: insights from simulation.
    Pulliam JRC; Bellan SE; Gambhir M; Meyers LA; Dushoff J
    Lancet Infect Dis; 2015 Oct; 15(10):1134. PubMed ID: 26461945
    [No Abstract]   [Full Text] [Related]  

  • 31. Vaccine trial launched to stop Ebola.
    Cohen J
    Science; 2018 May; 360(6390):694-695. PubMed ID: 29773723
    [No Abstract]   [Full Text] [Related]  

  • 32. [Ebola, the first vaccines available].
    Martin B; Volchkov V; Reynard O
    Med Sci (Paris); 2020 Nov; 36(11):1027-1033. PubMed ID: 33151849
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ebolavirus vaccines for humans and apes.
    Fausther-Bovendo H; Mulangu S; Sullivan NJ
    Curr Opin Virol; 2012 Jun; 2(3):324-9. PubMed ID: 22560007
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Recent Advances in Vaccines and Drugs Against the Ebola Virus].
    Zhu X; Yao C; Wei Y; Kou Z; Hu K
    Bing Du Xue Bao; 2015 May; 31(3):287-92. PubMed ID: 26470536
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Case fatality risk among individuals vaccinated with rVSVĪ”G-ZEBOV-GP: a retrospective cohort analysis of patients with confirmed Ebola virus disease in the Democratic Republic of the Congo.
    Coulborn RM; Bastard M; Peyraud N; Gignoux E; Luquero F; Guai B; Bateyi Mustafa SH; Mukamba Musenga E; Ahuka-Mundeke S
    Lancet Infect Dis; 2024 Jun; 24(6):602-610. PubMed ID: 38340736
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adenovirus-vectored Ebola vaccines.
    Gilbert SC
    Expert Rev Vaccines; 2015; 14(10):1347-57. PubMed ID: 26289977
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Still not ready for Ebola.
    Frieden TR
    Science; 2018 Jun; 360(6393):1049. PubMed ID: 29880661
    [No Abstract]   [Full Text] [Related]  

  • 38. Exploiting the reverse vaccinology approach to design novel subunit vaccines against Ebola virus.
    Ullah MA; Sarkar B; Islam SS
    Immunobiology; 2020 May; 225(3):151949. PubMed ID: 32444135
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ebola vaccine is safe and immunogenic, results show.
    Gulland A
    BMJ; 2015 Jan; 350():h524. PubMed ID: 25633684
    [No Abstract]   [Full Text] [Related]  

  • 40. Beyond vaccines: improving survival rates in the DRC Ebola outbreak.
    Kelly JD; Mukadi P; Dhillon RS
    Lancet; 2018 Jun; 391(10137):2321. PubMed ID: 29807665
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.